CC2D2A Activators
CC2D2A Activators encompass a collection of chemical compounds that indirectly promote the functional activity of CC2D2A by modulating various cellular signaling pathways. Compounds such as Forskolin, Isoproterenol, IBMX, PGE2, and Rolipram all function through mechanisms that raise intracellular cAMP levels, which is a critical second messenger in cellular signaling. The increased cAMP activates PKA, which can phosphorylate target proteins that are part of or interact with the CC2D2A-related pathways, thereby potentially enhancing CC2D2A function. PMA, as a PKC activator, and BIM, as a PKC inhibitor, may also influence CC2D2A activity by affecting the phosphorylation state of proteins within CC2D2A-related signaling networks. The modulatory effects of these compounds on protein kinase C signal transduction could result in either direct or indirect enhancement of CC2D2A's functional roles in the cell.
Additionally, Ionomycin and Thapsigargin enhance intracellular calcium levels, a critical factor in numerous signaling cascades that can impact CC2D2A activity through calcium-dependent proteins and interactions. FTY720, upon its phosphorylation, serves as a potent activator of S1P receptors, which may indirectly enhance CC2D2A activity through cytoskeletal dynamics and associated pathways. LY294002 disrupts PI3K/AKT signaling, whereas U0126 interferes with the MAPK pathway by inhibiting MEK1/2; both of these inhibitors could lead to enhanced CC2D2A activity by altering the regulatory mechanisms of proteins that may modulate CC2D2A's functional state. These activators do not directly bind to or alter the transcription or translation of the CC2D2A gene, but rather they work by influencing the intricate network of signaling pathways that ultimately govern the activity of the CC2D2A protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels, which could enhance CC2D2A activity through PKA-dependent signaling pathways, as PKA can phosphorylate various proteins that may interact with CC2D2A. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, increases cAMP levels via G protein-coupled receptor signaling, potentially enhancing CC2D2A activity by similar mechanisms as Forskolin, involving PKA signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX, a non-selective phosphodiesterase inhibitor, prevents the breakdown of cAMP, potentially leading to an indirect enhancement of CC2D2A activity through elevated cAMP and PKA signaling. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
PGE2, through its action on EP2/EP4 receptors, increases intracellular cAMP levels. This could indirectly enhance CC2D2A activity through cAMP-dependent pathways, notably involving PKA. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a selective PDE4 inhibitor, increases cAMP levels, possibly enhancing CC2D2A activity through cAMP-dependent PKA signaling and subsequent protein interactions. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA, a PKC activator, can modulate numerous signaling pathways including those that might intersect with CC2D2A functions, enhancing its activity through downstream effects. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin, a calcium ionophore, increases intracellular calcium levels, potentially enhancing CC2D2A activity through calcium-dependent signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin, a SERCA pump inhibitor, leads to increased intracellular calcium, which could enhance CC2D2A activity through calcium signaling and potential interactions with CC2D2A-related proteins. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
FTY720, after phosphorylation, acts as a S1P receptor modulator, which may enhance CC2D2A activity through S1P receptor-mediated signaling pathways influencing cytoskeletal dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, alters AKT signaling and other pathways that could indirectly enhance CC2D2A activity by affecting proteins that interact with or regulate CC2D2A. | ||||||